Summit Therapeutics and Akeso Inc. have potential to expand their ambitions beyond lung cancer with new Phase II data showing that ivonescimab, their bispecific antibody targeting PD-1 and VEGF, has strong efficacy in certain patients with head and neck, colorectal and breast cancers.
ESMO 24: Summit/Akeso Broaden Base Of Solid Tumor Indications For Anti-PD-1xVEGF Bispecific
Phase II data at the ESMO meeting showed promising efficacy for the drug beyond NSCLC, particularly in certain indications of colorectal and head-and-neck cancers.
